Skip to Main Content

ADVERTISEMENT

SCROLL TO CONTINUE WITH CONTENT

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

European Journal of Cancer

Home
Articles & Issues
Collections
- Back
- Special Issues
Authors
Journal
Subscribe
Societies
PracticeUpdate
More Periodicals

Advanced searchSave search

Please enter a term before submitting your search.

Submit
Log in
Register
Log in
- Submit
- Log in
Subscribe
Claim

Issue cover

October 2022

Volume 174p1-328

Issue cover

Current Issue
Issues in Progress
Articles in Press
Archive
- Articles in Press
- Archive

Previous IssueEORTC CLTG meeting on Cutaneous lymphomas: from molecules to PROs

Next Issue34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Select all

Download started.
Ok

Please select at least one article in order to proceed.

Breast cancer

Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study

Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study

Oranite Goldrat,
Manon De Cooman,
Audrey Mailliez,
...
Emmanuelle D'Orazio,
Isabelle Demeestere,
Christine Decanter

Published online: August 20, 2022

p134-141

Full-Text HTML
PDF

Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial

Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial

Si-Ye Chen,
Guang-Yi Sun,
Yu Tang,
...
Hui Fang,
Ye-Xiong Li,
Shu-Lian Wang

Published online: August 20, 2022

p153-164

Open Access

Full-Text HTML
PDF

Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models

Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models

Anna Z. de Boer,
Esther Bastiaannet,
Johannes Schetelig,
...
Linda de Munck,
Johanneke E.A. Portielje,
Liesbeth C. de Wreede

Published online: September 01, 2022

p212-220

Open Access

Full-Text HTML
PDF
Supplemental Materials

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial

Guillermo Villacampa,
Claudette Falato,
Laia Paré,
...
Joaquín Gavilá,
Aleix Prat,
Tomás Pascual

Published online: September 03, 2022

p232-242

Full-Text HTML
PDF
Supplemental Materials

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

Paolo Tarantino,
Samuel M. Niman,
Timothy K. Erick,
...
Meredith M. Regan,
Sara M. Tolaney,
Filipa Lynce

Published in issue: October 2022

p277-286

Full-Text HTML
PDF
Supplemental Materials

Lung cancer

TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer

TCF1⁺PD-1⁺ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer

Jaemoon Koh,
Sehui Kim,
Yeon Duk Woo,
...
Se-Hoon Lee,
Yoon Kyung Jeon,
Doo Hyun Chung

Published online: August 13, 2022

p10-20

Open Access

Full-Text HTML
PDF
Supplemental Materials

Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study

Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study

Wenxian Wang,
Gen Lin,
Yue Hao,
...
Guangyuan Lou,
Zhengbo Song,
Yongchang Zhang

Published online: August 13, 2022

p21-30

Full-Text HTML
PDF
Supplemental Materials

$Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group$

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group

Gabriele Antonarelli,
Chiara Corti,
Paolo Andrea Zucali,
...
Chiara Catania,
Fabio Conforti,
Tommaso De Pas

Published online: August 12, 2022

p31-36

Full-Text HTML
PDF

Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences

Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences

Fabrizio Tabbò,
Lucia Anna Muscarella,
Elisa Gobbini,
...
Paolo Graziano,
Silvia Novello,
Luisella Righi

Published online: August 28, 2022

p200-211

Full-Text HTML
PDF
Supplemental Materials

Gastrointestinal oncology

Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

Akihiro Ohba,
Hideki Ueno,
Satoshi Shiba,
...
Masafumi Ikeda,
Junji Furuse,
Takuji Okusaka

Published online: August 12, 2022

p40-47

Full-Text HTML
PDF
Supplemental Materials

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials

Claudia A.M. Fulgenzi,
Antonio D'Alessio,
Chiara Airoldi,
...
Alessandra Gennari,
Alessio Cortellini,
David J. Pinato

Published online: August 12, 2022

p57-67

Open Access

Full-Text HTML
PDF
Supplemental Materials

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

ZhiCheng Lai,
MinKe He,
XiaoYun Bu,
...
MinShan Chen,
Anna Kan,
Ming Shi

Published online: August 15, 2022

p68-77

Open Access

Full-Text HTML
PDF
Supplemental Materials

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry

Jordan Santucci,
Mark Tacey,
Benjamin Thomson,
...
Lara Lipton,
Peter Gibbs,
Belinda Lee

Published online: August 18, 2022

p102-112

Full-Text HTML
PDF

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database

Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database

Jan Franko,
Jun Yin,
Richard A. Adams,
...
Aimery de Gramont,
Qian Shi
for the ARCAD collaborators

Published online: August 20, 2022

p142-152

Full-Text HTML
PDF
Supplemental Materials

Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer

Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer

Eun Kyoung Hong,
Myriam Chalabi,
Federica Landolfi,
...
Monique van Leerdam,
Jeong Min Lee,
Regina Beets-Tan

Published online: August 24, 2022

p165-175

Full-Text HTML
PDF

Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study

Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study

Qiao-Xuan Wang,
Bin-Yi Xiao,
Yong Cheng,
...
Zhi-Zhong Pan,
Xiao-Shi Zhang,
Pei-Rong Ding

Published online: August 26, 2022

p176-184

Open Access

Full-Text HTML
PDF

Urologic oncology

Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure

Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure

Shinkyo Yoon,
Sang Joon Shin,
Ho Cheol Kim,
...
Inkeun Park,
Se Hoon Park,
Jae Lyun Lee

Published online: August 16, 2022

p81-89

Full-Text HTML
PDF

Gynecologic oncology

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial

Antonio González-Martín,
Christophe Desauw,
Florian Heitz,
...
Patricia Pautier,
Isabelle Ray-Coquard
on behalf of the PAOLA1/ENGOT-ov25 investigators

Published online: September 03, 2022

p221-231

Open Access

Full-Text HTML
PDF
Supplemental Materials

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer

Ana Oaknin,
Bradley J. Monk,
Ignace Vergote,
...
James Harnett,
Chieh-I Chen,
Krishnansu S. Tewari

Published online: July 31, 2022

p299-309

Open Access

Full-Text HTML
PDF
Supplemental Materials

Melanoma and skin cancers

Reporting of melanoma cell densities in the sentinel node refines outcome prediction

Reporting of melanoma cell densities in the sentinel node refines outcome prediction

Anja Ulmer,
Vanessa Pfefferle,
Vincent Walter,
...
Falko Fend,
Mihály Sulyok,
Hans Bösmüller

Published online: August 19, 2022

p121-130

Full-Text HTML
PDF
Supplemental Materials

Machine learning models demonstrate that clinicopathologic variables are comparable to gene expression prognostic signature in predicting survival in uveal melanoma

Machine learning models demonstrate that clinicopathologic variables are comparable to gene expression prognostic signature in predicting survival in uveal melanoma

Piotr Donizy,
Mateusz Krzyzinski,
Anna Markiewicz,
...
Bozena Romanowska-Dixon,
Przemyslaw Biecek,
Mai P. Hoang

Published online: September 03, 2022

p251-260

Full-Text HTML
PDF
Supplemental Materials

Sarcoma

Incidence and Outcome of Breast Sarcomas in England (2013–2018): An analysis from the National Cancer Registration and Analysis Service

Incidence and Outcome of Breast Sarcomas in England (2013–2018): An analysis from the National Cancer Registration and Analysis Service

Ahmed M,
Collins S,
Franks J,
...
Bacon A,
Paley L,
Strauss SJ

Published online: August 12, 2022

p48-56

Full-Text HTML
PDF
Supplemental Materials

New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas

New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas

Georgios Kantidakis,
Saskia Litière,
Anouk Neven,
...
Bernd Kasper,
Marta Fiocco,
Hans Gelderblom

Published online: September 08, 2022

p261-276

Open Access

Full-Text HTML
PDF
Supplemental Materials

Hematology

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

María-Victoria Mateos,
Miguel-Teodoro Hernández,
Carlos Salvador,
...
Joan Bladé,
Juan-José Lahuerta,
Jesús San-Miguel

Published online: September 03, 2022

p243-250

Full-Text HTML
PDF

Tumour Immunology and Immunotherapy

Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors

Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors

Cho-Han Chiang,
Cho-Hung Chiang,
Chun-Yu Peng,
...
Katharine Ching Chung,
Cho-Hsien Chiang,
Cheng-Ming Peng

Published online: August 11, 2022

p1-9

Full-Text HTML
PDF
Supplemental Materials

Metachronous malignancies after response to checkpoint inhibition

Mirjam A. de Visser,
Francois B. Verschaeve,
Lot A. Devriese,
Bart Neyns,
Karijn P.M. Suijkerbuijk

Published online: August 17, 2022

p99-101

Full-Text HTML
PDF

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study

Edwin A. Basak,
Niels S. Vermeer,
Karlijn de Joode,
...
Joachim G.J.V. Aerts,
Arjen Joosse,
Ron H.J. Mathijssen

Published online: August 18, 2022

p113-120

Open Access

Full-Text HTML
PDF
Supplemental Materials

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Jean-Philippe Foy,
Andy Karabajakian,
Sandra Ortiz-Cuaran,
...
Jérôme Fayette,
Chloé Bertolus,
Pierre Saintigny

Published online: August 26, 2022

p287-298

Full-Text HTML
PDF
Supplemental Materials

Other

An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data

An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data

Kathryn Schutte,
Fabien Brulport,
Sana Harguem-Zayani,
...
Thomas Clozel,
Samy Ammari,
Nathalie Lassau

Published online: August 16, 2022

p90-98

Open Access

Full-Text HTML
PDF
Supplemental Materials

Follow-up strategy and survival for five common cancers: A meta-analysis

Follow-up strategy and survival for five common cancers: A meta-analysis

Boris Galjart,
Diederik J. Höppener,
Joachim G.J.V. Aerts,
Christiaan H. Bangma,
Cornelis Verhoef,
Dirk J. Grünhagen

Published online: August 26, 2022

p185-199

Open Access

Full-Text HTML
PDF
Supplemental Materials

Correspondence

Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) – A case series

Christian Rausch,
Charlotte Schwicht,
Daphne Doedens,
Roswitha Forstpointner,
Christoph Benedikt Westphalen,
Volker Heinemann

Published online: August 12, 2022

p37-39

Full-Text HTML
PDF

Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity

Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity

Vasiliki Nikolaou,
Chryssoula Papageorgiou,
Elizabeth Lazaridou,
Panagiotis Diamantopoulos,
Zoe Apalla

Published online: August 15, 2022

p78-80

Full-Text HTML
PDF

The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: Insights from National Inpatient Sample

The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: Insights from National Inpatient Sample

Sahith Reddy Thotamgari,
Udhayvir Singh Grewal,
Mohammad Alfrad Nobel Bhuiyan,
Zain Ul Abideen Asad,
Paari Dominic

Published online: August 20, 2022

p131-133

Full-Text HTML
PDF

Re: Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial

The jury is still out

Lei Duan,
Lu Yang,
Bohan Zhang,
Jiaxu Liao,
Xiaohua Zheng

Published online: August 03, 2022

p310-312

Full-Text HTML
PDF

Response to letter entitled: Re: ‘Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with micro-vascular invasion: A randomized controlled trial’

Changying Shi,
Yong Li,
Li Geng,
...
Jiongjiong Lu,
Mianshun Pan,
Jiamei Yang

Published online: July 18, 2022

p313-314

Full-Text HTML
PDF

Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib

Phil Bennett,
Alison Finall,
Filomena Medeiros,
Gareth Gerrard,
Phillipe Taniere

Published online: August 04, 2022

p315-317

Full-Text HTML
PDF

Response to letter entitled: Re: ‘Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla^TM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib'

Not looking back

Hazel O'Sullivan,
Paolo D. d'Arienzo,
Nadia Yousaf,
Wanyuan Cui,
Sanjay Popat

Published online: August 07, 2022

p318-320

Full-Text HTML
PDF

Letter re: “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”

Alessandro Rizzo,
Giovanni Brandi

Published online: July 21, 2022

p321-322

Full-Text HTML
PDF

Reply to comment on “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”

Ahmed Sayed,
Omar M. Abdelfattah,
Daniel Addison

Published online: July 21, 2022

p323-324

Full-Text HTML
PDF

Corrigenda

Corrigendum to ‘Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128–139]

Corrigendum to ‘Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128–139]

Maria M. Karsten,
Robert Roehle,
Sarah Albers,
...
Matthias Rose,
Friedrich Kühn,
Jens-Uwe Blohmer

Published online: August 12, 2022

p325-327

Open Access

Full-Text HTML
PDF

Corrigendum to “518 Poster - BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance” [Eur J Cancer 138 (Supplement 1) (October 2020) S106–S107]

Midas M. Kuilman,
Architha Ellappalayam,
Lorenza Mittempergher,
...
Bob Chan,
Rajith Bhaskaran,
Annuska M. Glas

Published in issue: October 2022

p328

Full-Text HTML
PDF

Login to your account

Email/Username

Password

Forgot password?

Remember me

Don’t have an account?

Create a Free Account

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email*

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

Copyright © 2023 Elsevier Inc. except certain content provided by third parties.

Privacy Policy
Terms and Conditions
Accessibility
Help & Contact

RELX